EU/3/15/1435

About

On 12 February 2015, orphan designation (EU/3/15/1435) was granted by the European Commission to Covis Pharma S.à.r.l., Luxemburg, for nitroglycerin for the treatment of systemic sclerosis.

Key facts

Active substance
Nitroglycerin
Disease / condition
Treatment of systemic sclerosis
Date of first decision
12/02/2015
Outcome
Positive
EU designation number
EU/3/15/1435

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Covis Pharma S.à.r.l.
Atrium Business Park
33 rue du Puits Romains - Boite 6
L - 8070 Bertrange
Luxembourg
Tel. +35 228 2651
E-mail: regulatory@covispharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating